UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40228 LONGEVITY HEALTH HOLDINGS, INC. (Exact Name of Registrant as Specified in its Charter) ( State or other jurisdiction of incorporation or organization) (I.R.S. Emp ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40228 LONGEVITY HEALTH HOLDINGS, INC. (Exact Name of Registrant as Specified in its Charter) Registrant's telephone number, including area code: (919) 313-9633 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40228 LONGEVITY HEALTH HOLDINGS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 86-1645738 (State or other jurisdiction of incorporation or or ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Delaware 001-40228 86-1645738 (Commission File Number) (IRS Employer Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Identification No.) (Exact name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation) Date of Report (Date of earliest event reported): May 15, 2025 Longevity Health Holdings, Inc. 2403 Sidney Street, Suite 300 Pittsburgh, Pennsylvania 1520 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40228 LONGEVITY HEALTH HOLDINGS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 86-1645738 (State or other jurisdiction of incorporation or o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40228 LONGEVITY HEALTH HOLDINGS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 86-1645738 ( State or other jurisdiction of incorporation or organ ...

(Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 OR FORM 10-Q ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40228 Securities registered pursuant to Section 12(b) of the Act: | | Trading | | | --- | --- | --- | | Title of each class | Symbol(s) | Name of each exchange ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40228 CARMELL CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 86-1645738 ( State or other jurisdiction of incorporation or organization) ...

业绩相关 - 2024年和2023年第一季度，公司持续经营业务净亏损分别为3,553,162美元和1,828,715美元[132] - 2024年和2023年第一季度，经营活动现金流分别为 -1,075,778美元和 -475,959美元[132] - 截至2024年3月31日，公司现金为892,161美元，负营运资金为1,716,328美元[128] - 2024年4月4日，公司私募配售普通股获约300万美元毛收入[32][33] - 2024年3月26日，公司出售子公司AxoBio，对价含3,845,337股普通股等[35][36] 用户数据 - 截至2024年5月23日，公司普通股登记持有人约232人[172] - 截至2024年5月23日，公司普通股流通股数量为20,817,493股[42] 未来展望 - 预计2024年推出新护肤品，需大量额外资金[73] - 计划采用全渠道分销策略销售产品[191] - 计划在欧盟申请CE标志批准[79] 新产品和新技术研发 - 正在开发男士产品线和局部护发产品线[24][183] - 产品管道包括创新再生骨和组织愈合产品[24][183] - 开发的微乳液配方不使用矿物或植物油，非致粉刺性[24][183][188] - 首款美容护肤产品Carmell G.L.E.E于2024年3月商业推出，另有九款护肤产品在研发中[191] - BHA和THA产品候选基于从CMU获得的专利，BHA被FDA指定为组合产品[193] 市场扩张和并购 - 2024年3月26日，公司完成出售子公司AxoBio[35][36] 其他新策略 - 重新确定产品候选药物开发优先级，专注美容护肤和护发产品线近期商业化[77]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40228 CARMELL CORPORATION (Exact Name of Registrant as Specified in its Charter) Delaware 86-1645738 ( State or other jurisdiction of incorporation or organization ...